Transgene Biotek has received patent in the US for its novel molecule to be developed for treatment of liver cancer. The company’s novel molecule ‘miRNA 101’ for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed.
The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics. This granting of USA patent is a significant step in moving ahead with the development of this novel drug.
Transgene Biotek is involved in the development of several cutting edge technologies. The company is engaged in manufacturing drugs for New Drug Delivery System (NDDS), Biogeneries and Human Vaccines.
